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Inhibitory effect of IL-17 on neural stem cell
proliferation and neural cell differentiation
Zichen Li1,2†, Ke Li1†, Lin Zhu2*, Quancheng Kan2, Yaping Yan1, Priyanka Kumar1, Hui Xu1,
Abdolmohamad Rostami1 and Guang-Xian Zhang1*
Abstract
Background: IL-17, a Th17 cell-derived proinflammatory molecule, has been found to play an important role in the
pathogenesis of autoimmune diseases, including multiple sclerosis (MS) and its animal model, experimental
autoimmune encephalomyelitis (EAE). While IL-17 receptor (IL-17R) is expressed in many immune-related cells,
microglia, and astrocytes, it is not known whether IL-17 exerts a direct effect on neural stem cells (NSCs) and
oligodendrocytes, thus inducing inflammatory demyelination in the central nervous system.
Methods: We first detected IL-17 receptor expression in NSCs with immunostaining and real time PCR. We then
cultured NSCs with IL-17 and determined NSC proliferation by neurosphere formation capability and cell number
count, differentiation by immunostaining neural specific markers, and apoptosis of NSCs by flow cytometry.
Results: NSCs constitutively express IL-17R, and when the IL-17R signal pathway was activated by adding IL-17 to
NSC culture medium, the number of NSCs was significantly reduced and their ability to form neurospheres was
greatly diminished. IL-17 inhibited NSC proliferation, but did not induce cytotoxicity or apoptosis. IL-17 hampered
the differentiation of NSCs into astrocytes and oligodendrocyte precursor cells (OPCs). The effects of IL-17 on NSCs
can be partially blocked by p38 MAPK inhibitor.
Conclusions: IL-17 blocks proliferation of NSCs, resulting in significantly reduced numbers of astrocytes and OPCs.
Thus, in addition to its proinflammatory role in the immune system, IL-17 may also play a direct role in blocking
remyelination and neural repair in the CNS.
Keywords: NSCs, IL-17
Background
Due to the capability of NSCs to undergo self-renewal and
to differentiate into multiple cell types, NSC-based trans-
plantation has become a potential therapeutic approach in
the treatment of neurological disorders such as multiple
sclerosis (MS) [1,2]. The majority of NSCs come from two
areas: the subventricular zone (SVZ) and the subgranular
zone of the hippocampus [3,4]. Recent reports suggest that,
under normal conditions, proliferation and differentiation of
NSCs are necessary for neural repair [5]. However, this
function is dramatically reduced in MS, resulting in the
breakdown of spontaneous remyelination and neural re-
covery [6].
Interleukin-17 (IL-17), an inflammatory cytokine gener-
ated by Th17 cells, has been implicated in the development
of MS and its animal model, experimental autoimmune
encephalomyelitis (EAE) [7,8]. By increasing production of
several chemokines and cytokines in the central nervous
system (CNS) and modulating the inflammatory response,
the IL-17/IL-17R pathway plays a critical role in the devel-
opment of MS [9,10]. Although EAE and MS have been
considered typical Th1 cell-mediated diseases, growing evi-
dence suggests that Th17 cells play an important role in
the effector mechanisms of these, and other, autoimmune
diseases [9,11-13]. Thus, any factor that directly impairs
development of Th17 cells, or a deficiency in factors that
promote this lineage (IL-1, IL-6, IL-23), consistently abro-
gates EAE [14,15]. IL-17 is the hallmark cytokine of Th17
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lineage, which binds to the heteromeric transmembrane
receptor, resulting in recruitment of Act1 and formation
of a signaling complex that facilitates inflammatory re-
sponses [16]. Mice that lack the IL-17 or IL-17 receptor
are less susceptible to EAE induction, and IL-17-specific
inhibition attenuates inflammation, suggesting that IL-17
signaling plays a critical role in the effector stage of EAE
[17]. Importantly, increased IL-17 production and mRNA
expression have been reported in MS patients with active
disease [18,19].
However, to date, there have been no reports about
the action of IL-17 on NSCs, or on the question whether
NSCs express IL-17 receptors. In the current study, we
thus address this important question, and investigate the
effect of IL-17 on NSC proliferation, differentiation and
cell death.
Methods
NSC cultures and differentiation
Mouse NSCs were generated from 14-day-old embryos
(E14) from C57Bl/6 mice. Briefly, whole brains of
C57BL/6 E14 mouse embryos were harvested under
sterile conditions and placed in DMEM medium. After a
brief washing with DMEM medium, tissues were cut
into 1 mm3 pieces and suspended in 2 ml 0.25% trypsin
with EDTA (Invitrogen, NY, USA), mechanically dissoci-
ated for 2 min and incubated at 37°C for 30 min. After
filtration through a 70 μm cell strainer (BD Bioscience,
San Jose, CA), the cell suspension was washed twice
with 10 ml DMEM medium. Cells were resuspended in
serum-free DMEM/F-12 (Invitrogen, NY, USA) supplied
with 2% B27 supplements (Invitrogen, NY, USA), 20 ng/ml
epidermal growth factor (EGF, Peprotech, Rocky Hill, NJ,
USA) and 20 ng/ml basic fibroblast growth factor (b-FGF,
Peprotech, Rocky Hill, NJ), along with 100 IU/ml penicillin
and 100 μg/ml streptomycin (Sigma-Aldrich, MI, USA).
Cells were then transferred to poly-L-lysine coated 6-well
plates (BD Bioscience, San Jose, CA) at a density of 2 × 105
cells/ml and maintained in culture at 37°C. Culture medium
was changed every 3 days. Neurospheres were formed after
3-4 days of culture. For passaging, free-floating neurospheres
were collected and dissociated with Accutase cell detach-
ment solution (Innovative Cell Technologies, San Diego,
CA) into small neurospheres or single cells and re-seeded
at a density of 1 × 105 cells/ml in the same medium. NSCs
at passage 4-15 were used in all in vitro experiments. To in-
duce NSC differentiation, dissociated single cells or small
neurospheres were incubated in stem cell differentiation
medium (NSC basal medium plus 10% NSC differentiation
supplements, Stemcell Technologies) for 7 to 14 days and
processed for immunofluorescence. All animal protocols
were approved by the Institutional Animal Care and Use
Committee of Thomas Jefferson University, following NIH
guidelines.
IL-17R immunostaining
Cells grown on coated cover slips for two days and fixed
with 4% paraformaldehyde in PBS (Cellgro Mediatech,
USA) were blocked in PBS/0.1% saponin/5% goat serum
and incubated with primary antibody at 4°C overnight.
Rabbit anti-IL-17R antibody (Santa Cruz, CA, USA) was
used to determine IL-17 receptor. Briefly, cells were cul-
tured on slides with stem cell medium, then were washed
2 times with PBS for 5 min, fixed in 3.7% PFA for 10 min
at room temperature and washed 3 times with PBS.
Blocking was performed in 10% of appropriate serum for
2 hours at room temperature. Cells were then incubated
with anti-IL-17R (1:100) overnight at 4°C. After being
washed twice in PBS with 0.5% Triton X-100, secondary
antibodies were applied for 1 h at room temperature. Cells
were then washed, mounted onto Mowiol, and visualized
by fluorescence microscopy (Olympus I X-80) with a 20
PlanApo oil immersion objective (1.0 numerical aperture).
For visualizing all cells, nuclei were counterstained with
DAPI. In this experiment omitting primary antibody was
used as control. Images were acquired with a SensiCamQE
High Performance CCD Camera.
Real-time PCR
Total RNA was isolated from NSCs in the same culture
conditions as those used in immunostaining. RNAs isolated
from primary oligodendrocytes (>93% GalC+) of wild type
B6 mice served as IL-17R positive control [20], and of IL-
17R-deficient mice (the Jackson Laboratory) as negative
control. For quantitative real-time PCR of IL-17R, specific
primers were generated as follows: IL-17RrealF: 5′-AGGT
CCAGCCCTTCTTCAGCA-3′, IL-17RrealR: 5′-GCTTG
GGAACTGTGGTATTTGA- -GATTA-3′. High Capacity
cDNA Reverse Transcription Kit (Invitrogen), RNeasy Mini
Kit and QuantiFast SYBR Green PCR Kit (QIAGEN) were
used for real-time PCR according to the manufacturer’s
instructions.
Analysis of neurosphere growth
To determine the neurosphere volume of stimulated NSCs,
these cells were cultured at 200 cells/ml in 96-well plates.
These cells were cultured in the presence of IL-17 at differ-
ent concentrations (0, 5, 10, 25, 50, 100 ng/ml) for 96 hours.
NSCs in separate wells were cultured in the presence of
TNF-α at 25 ng/ml as positive control, given its cytotoxicity
to neural cells [20], while IL-10 at 50 ng/ml was also used
as control, which does not interfere NSC proliferation [21].
The number of living neurospheres was counted under in-
verse microscope (ECLIPSE TS-100, Nikon, Japan).
Analysis of cell numbers
To determine the actual number of cells in neurospheres,
we did a cell number count after dissociating neurospheres
into single cells. Briefly, NSCs were cultured at 1.5 × 105
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cells/ml in 24 well plates. These cells were cultured in the
presence of IL-17 at different concentrations (0, 5, 10, 25,
50, 100 ng/ml) for 96 hours, and in the presence of IL-10
at 50 ng/ml [21] or TNF-α at 25 ng/ml [20] as control.
Neurospheres were collected, dissociated and cell number
was counted under inverse microscope (ECLIPSE TS-100,
Nikon, Japan).
MAPK signaling pathway analysis
We then determined p38 MAPK signaling activation
in NSCs by western blot. Briefly, cells were cultured at 2 ×
105 cells/ml in 6-well plates for 2 days. Two wells were
added with IL-17; 2 wells were added with IL-17 and in-
hibitor of p38 MAPK (SB203580) (Cell Signaling) at 15
mM. Then cells were lysed in lysis buffer (Cell Signaling)
supplemented with protease/phosphatase inhibitor cock-
tail (Cell Signaling). Cell lysates were separated by 12%
Tris-Glycine Gels (NovexW 12% Tris-Glycine Mini Gels
1.0 mm, 12-well) and transferred onto Immun-Blot PVDF
membrane (Bio-Rad Laboratories). Membranes were blot-
ted with primary antibodies followed by incubation with
HRP-conjugated secondary antibodies. The blots were de-
veloped by ECL reagents and exposed on HyperFilmTM
(Amersham). The following antibodies were used for west-
ern blotting: p38 MAPK (D13E1) XPW Rabbit mAb (Cell
Signaling), β-Actin (C-4) (Santa Cruz Biotechnology);
anti-rabbit IgG HRP-linked antibody (Cell Signaling) and
goat anti-mouse IgG-HRP (Santa Cruz Biotechnology).
Analysis of cell death and apoptosis
After incubation at room temperature for 5 min in the
dark, cells were trypsinized and resuspended in 50 μL
staining buffer containing 100 ng propidium iodide (PI)
(Sigma-Aldrich, MI, USA), and then analyzed by flow cy-
tometry. Dead cells were defined as PI positive. Percent-
ages of PI positive cells among cells were calculated.
To assess apoptosis of stimulated cells, NSCs were cul-
tured at 2 × 105 cells/ml in 96 well plates and stimulated
with IL-17 (25 ng/ml) for 48 hours. Cells were harvested,
then stained with Annexin-V (BD Biosciences, CA, USA),
and PI (Sigma-Aldrich, MI, USA) according to the manu-
facturer’s instructions. Briefly, cells were washed twice with
PBS and then resuspended in binding buffer. 5 μl Annexin-
V was added to the 100 μl solution in a tube and incubated
for 15 min at room temperature in the dark. Cell apoptosis
was analyzed by flow cytometry within 1 hour. Apoptotic
cells were defined as Annexin-V positive.
Analysis of cytotoxicity
To determine the cytotoxicity of IL-17 on stimulated NSCs,
extracellular LDH activity was detected with an LDH Cyto-
toxicity Detection Kit (Clontech Laboratories, Mountain
View, CA) following the manufacturer’s instructions.
Briefly, NSCs were cultured at 1 × 105 cells/ml in 96-well
plates. These cells were cultured in the presence of IL-17 at
different concentrations (0, 5, 10, 25, 50, 100 ng/ml) for 48
hours. The plates were then centrifuged at 250 g for 10
min., and 100 μl of supernatant from each well was trans-
ferred into the corresponding well of a 96-well flat-bottom
plate. 0.1 ml of freshly prepared Reaction Mixture was
added to each well and incubated for up to 30 min at room
temperature, protected from light. Absorbance of the sam-
ples was measured and the cytotoxicity percentage was cal-
culated according to the manufacturer’s instructions.
Proliferation assay
[3H]-thymidine DNA incorporation was measured in
stimulated cells. Briefly, NSCs were cultured at 1.5 × 104
cells/ml in 96-well plates. These cells were cultured in the
presence of IL-17 at different concentrations (0, 5, 10, 25,
50, 100 ng/ml) for 48 hours. 1 μCi/well 3H-Thymidine
was added to each well. Plates were incubated for 18
hours. 30 μl NaOH 1N solution (Sigma Diagnostics, MO)
was added to each well to lyse the cells; then 30 μl hydro-
chloric acid 1N solution was added to each well to
neutralize NaOH (Fisher Scientific, NJ). After supernatant
had been thoroughly mixed, radioactivity was measured in
a beta-counter.
Immunostaining
Cells grown on coated coverslips and fixed with 4%
paraformaldehyde in PBS (Cellgro Mediatech, USA)
were blocked in PBS/0.1% saponin/5% goat serum and
incubated with primary Abs at 4°C overnight. β-III-tubu-
lin was used as neuron marker; GFAP as an intracellular
astrocytic marker; NG2 as oligodendrocyte progenitor
cell (OPC) marker and Sox2 as NSC marker. Briefly,
cells were cultured on slides with stem cell medium,
washed 2 times with PBS for 5 min, fixed in 3.7% PFA
for 10 min at room temperature and washed 3 times
with PBS. Blocking was performed in 10% appropriate
serum for 2 hours at room temperature. Cells were then
incubated with anti-β-III-tubulin (1:150); anti-GFAP
(1:150); anti-NG2 (1:150) and anti-SOX2 (1:100) over-
night at 4°C. After washing twice with PBS containing
0.5% Triton X-100, secondary antibodies were applied
for 1 h at room temperature. Cells were then washed,
mounted onto Mowiol, and visualized by fluorescence
microscopy (Olympus I X-80) with a 20 PlanApo oil
immersion objective (1.0 numerical aperture). For visual-
izing all cells, the nuclei were counterstained with DAPI.
In this experiment omitting the primary antibody was used
as control. Images were acquired with a SensiCamQE High
Performance CCD Camera.
Statistical analysis
Data are presented as the mean ± SE of 3–6 independ-
ent experiments, each carried out in triplicate or
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quadruplicate. Comparisons were analyzed using one-
way analysis of variance (ANOVA), followed by a post-
hoc Bonferroni's multiple comparison test. Statistical
significance was established at p<0.05. The tables and
graphs of the original data were produced using
GraphPad Prism software version 5.00 for Windows
(GraphPad, USA).
Results
NSCs express IL-17R
Before investigating the direct effect of IL-17 on NSCs,
we measured the expression level of IL-17R in NSCs.
With immunofluorescence, we found that IL-17R is
expressed in in vitro cultured NSCs (Figure 1a, b and c).
IL-17R expression on NSCs was further confirmed by
RT-PCR, with spinal cord tissues of wild type mice as
positive control [20] and of IL-17R knockout mice as
negative control (Figure 1d). These findings demonstrate
that IL-17R is expressed constitutively in NSCs, indicat-
ing that IL-17 can exert a direct effect on these cells.
IL-17 can reduced neurosphere formation and inhibit NSC
number increase
To investigate the effects of IL-17 on neurosphere forma-
tion and cell number changes in NSCs, we compared
NSC in culture medium with IL-17. Single NSCs from
passage 10 onwards were cultured in 96 well plates. After
4 days’ culture with IL-17 at different concentrations (0, 5,
10, 25, 50, 100 ng/ml), neurosphere volumes were then
measured. We found that IL-17 can significantly reduce
the number of newly formed neurospheres in culture
medium (Figure 2a), while there was no difference in the
formation of NSC neurospheres at various IL-17 concen-
trations. We therefore analyzed the actual cell number
change after stimulation. As expected, IL-17 significantly
decreased the cell number in the treated group compared
with the medium control (Figure 2b). Similar results were
obtained when TNF-α was added as a positive control,
while there was no influence when IL-10 was added as a
negative control (Figure 2c and 2d), consistent with previ-
ous observation [21].
IL-17 does not induce NSC apoptosis
We investigated whether IL-17 would induce apoptosis
of NSCs. As shown in Figure 3, Annexin-V positive cells
were significantly decreased in NSCs upon treatment
with IL-17 compared with the control group. At the
same time, FACS analysis revealed a decrease in the per-
centage of PI positive NSCs (Figure 3) upon treatment
with IL-17 compared with controls. Our data provide
evidence that the inhibitory role of IL-17 in NSC prolif-
eration does not result from cell apoptosis.
IL-17 does not enhance cytotoxicity in NSCs
Cytotoxicity is one of the major causes of decrease in cell
numbers. To investigate whether IL-17 has cytotoxicity to
NSCs when inhibiting NSC proliferation, LDH release
from NSCs was detected after treatment with IL-17 for 2
days. According to the manufacturer’s instructions, we
mixed medium with Reaction Mixture and measured the
a.
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Figure 1 IL-17R expresses in NSCs. Dissociated single cells were incubated in stem cell culture or differentiation medium in 12-well plates for 2
days and processed for immunofluorescence. (a) Immunocytochemistry images of neural stem cells cultures labeled for IL-17R (green) and
counterstained with the nuclei dye DAPI (blue). (b) IL-17R antibody was omitted to serve as control. Magnification ×20 for A, ×20 for B. (c) Plot
depicts the percentage of IL-17R positive cells. (d) RT-PCR for IL-17R expression in NSCs. Primary oligodendrocytes (>93% GalC+) of wild type B6
mice served as positive control and of IL-17R knockout mice as negative control. Mean percentages were determined from five independent
experiments. WT: wild type.
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absorbance of the samples. Our data showed that, whether
or not NSCs were treated with IL-17, there was no signifi-
cant change in LDH release from NSCs (Figure 4a). Our
data demonstrate that IL-17 shows no cytotoxicity in
NSCs.
IL-17 inhibits NSC proliferation, partially through
activating p38 MAPK pathway
Having shown that the reduction of NSC number was not
due to IL-17-induced cell killing, we next explored whether
this reduction resulted in an inhibitory effect of IL-17
on NSC proliferation. We used 3H-TdR incorporation
to measure proliferation and found that adding IL-17 to
culture significantly inhibited proliferation of cultured
NSCs (P<0.001; Figure 4b). These results indicate that
IL-17 plays an inhibitory role in NSC proliferation.
We then explored the downstream signal pathway for
IL-17 induced proliferation decrease. To determine
whether activation of p38 MAPK is involved in IL-17
stimulation in NSCs, we used SB203580 (p38 inhibitor)
to block p38 MAPK. Our data show that decrease in
newly formed neurosphere and total cell number after
IL-17 treatment is inhibited by adding SB203580 (15
μM) to culture medium (Figure 5a). The induction of
p38 MAPK by IL-17 and inhibition by SB203580 in
NSCs were confirmed by western blot (Figure 5b).
IL-17 interferes with NSC differentiation
A crucial property of NSCs is the capacity to differentiate
into more specialized cells. To study the role of IL-17 acti-
vation in NSC differentiation, we cultured NSCs on a
poly-L-lysine pre-coated micro glass cover in 12-well cul-
ture plates with differentiation culture medium for 14 days
in order to induce differentiation of NSCs [1]. Cultured
cells were treated with IL-17. We used the following
neural specific markers: β-III-tubulin (neurons), GFAP
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Figure 2 IL-17 induces a decrease in both neurosphere volume and cell number. NSCs were cultured at 400 cells/ml in 96- or 12-well plates
and treated with IL-17, TNF-α and IL-10 for 96 h, as described in Materials and Methods. (a) NSCs treated with different concentrations of IL-17;
(b) Number of NSCs treated with different concentrations of IL-17; (c) NSCs treated with IL-17 (25 ng/ml), TNF-α (25 ng/ml) and IL-10 (50 ng/ml) alone;
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(astrocytes), NG2 (OPCs) and SOX2 (undifferentiated
NSCs). As shown in Figure 6, while the number of β-III-
tubulin positive neurons was not significantly reduced,
adding IL-17 to NSC culture resulted in a decrease in
numbers of GFAP+ astrocytes, NG2+ OPCs and SOX2+
undifferentiated NSCs. These results indicate that IL-17
stimulation negatively influences NSC differentiation into
later stages of neural cells.
Discussion
NSCs are a unique population of cells that exhibit stem
cell properties, including self-renewal (production of a
large number of progeny) and multipotency (differenti-
ation of the progeny into the three primary CNS pheno-
types: neurons, astrocytes and oligodendrocytes) [22].
NSCs that have been isolated from adult brain can be
maintained in vitro for extended periods of time without
losing their proliferation or differentiation potential
[22,23]. Because NSCs have the ability to support neuro-
genesis within restricted areas throughout adulthood and
can undergo extensive in vitro expansion, they have been
proposed as a renewable source of neural precursors for
regenerative transplantation in various CNS diseases, in-
cluding degenerative disorders, injury and cancer [24,25]
and EAE [21,26,27]. These cells reached multiple demye-
linating areas of the CNS and ameliorated EAE clinically
and pathologically to a similar extent when injected either
intravenously or intraventricularly [27]. However, in in-
flamed foci, such as occur in MS and EAE, which are a
hostile microenvironment for NSCs, the migration and
proliferation of NSCs are inhibited, resulting in a failure of
spontaneous remyelination and neural repair [28]. It is
thus important to identify immune cells and/or
proinflammatory mediators that are responsible for this
pathogenic outcome.
IL-17A, which has been called IL-17, is the prototypical
cytokine of the IL-17 family, which comprises IL-17A-F
[16]. IL-17A and IL-17F trigger signaling via their receptor,
a heterodimeric molecule composed of IL-17RA and IL-
17RC [29]. IL-17 activates NFκB signaling and induces
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several proinflammatory cytokines and chemokines, in par-
ticular, CCL20, which can attract CCR6-expressing Th17
cells [30]. In the CNS, IL-17 activates microglial cells [31]
and induces oligodendrocyte cell death [20]; it is thus
pathogenic in CNS inflammatory demyelination. However,
the role of IL-17 signaling in NSCs is not yet known. This
question is important given the critical role of these cells in
remyelination and neural repair following brain damage.
The capacity of NSCs for self-renewal and for generating
functional differentiated cells makes them an attractive po-
tential therapeutic tool for the treatment of neurological
disorders. Indeed, NSCs have recently emerged as a poten-
tial therapeutic approach in the treatment of MS [2]. In the
present study, we demonstrate that IL-17 significantly re-
duces NSC number by inhibiting the proliferation of these
cells, and is thus a novel mechanism underlying the patho-
genesis of Th17 cells in the development of CNS inflamma-
tory demyelinating diseases such as MS.
Previous studies have shown that IL-17/IL-17R interac-
tions use TRAF6 to transduce its signal in immune cells
[32], and is a well-studied multi-pathway process of cell
death in neural cells [33]. At the same time, IL-17 medi-
ated activation of JNK1/2 is reported to be involved in cell
death [34,35]. Moreover, IL-17R has been found to express
in oligodendrocytes, the myelinating cells, and adding IL-
17 to culture induces significant oligodendrocyte apop-
tosis [20]. We hypothesized that NSC apoptosis would be
increased after treatment with IL-17. To this end, we
tested whether IL-17 had induced NSC apoptosis. Surpris-
ingly, our findings showed that, compared with control,
apoptosis in treated NSCs had decreased. Further, we also
investigated whether this proinflammatory mediator in-
duced cytotoxicity of these cells, which is an important
pathway involved in cell death [36,37]. Similarly, IL-17 did
not induce lactate dehydrogenase (LDH) release, which is
a reliable and simple approach for defining cell death [38].
Together, these results indicate that the decrease in cell
number in treated NSCs resulted from cell proliferation
inhibition, not cell death.
The mitogen activated protein kinase (MAPK) family is
composed of three main members, including JNK, ERK
and p38 MAPK, which can translocate from cytoplasm to
nucleus, and induce a series of inflammatory actions in
cells [39]. Among them, the interaction between p38
MAPK and IL-17 is well known for its important role in
immunity. For example, IL-17 stimulation induced a high
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Figure 4 IL-17 does not induce cell death in NSCs, but decreases NSC proliferation. Cells were cultured in 96-well plates and treated with
IL-17 for 48 h as described in Materials and Methods. (a) Plots depict LDH release in NSCs treated with different concentrations of IL-17; (b) Plots
depict radioactivity in NSCs treated with different concentrations of IL-17. Data represent mean ± SE in triplicate samples from four independent
experiments. NS, not significant.
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level of proinflammatory cytokine production via the
Erk1/2, p38 MAPK, PI3K/Akt, and NF-κB pathways [40].
On the other hand, activation of p38 MAPK signaling
pathway is essential for in vitro and in vivo IL-17 produc-
tion, and is required for the development and progression
of CNS proinflammatory demyelination [41]. p38 MAPK
signaling has also been found to be involved in insufficient
NSC proliferation; targeting p38 restored these cells and
corrected neuromotor deficits in an ataxia-telangiectasia
mouse model [42]. The importance of p38 MAPK acti-
vation in the inhibition of NSC proliferation has also
been observed by culturing NSCs with IL-1β, another
proinflammatory cytokine that is involved in CNS pro-
inflammatory demyelination [43]. We demonstrated that
the p38 MAPK level in NSCs increased after IL-17 stimu-
lation and that p38 MAPK inhibitor can release the anti-
proliferation effect of IL-17. We also showed that the
inhibition of NSC proliferation by IL-17 can be partially
reversed by p38 MAPK inhibitor. Thus, in addition to its
proinflammatory role in the immune system, IL-17 also
play a direct role in blocking myelination and neural repair
in EAE/MS though the MAPK pathway.
The capacity of NSCs for neural cell differentiation
makes these cells a promising potential therapeutic tool for
the treatment of nervous system disorders [1,2]. Increasing
evidence suggests that NSCs go through a process of self-
renewal, proliferating and differentiating into the appropri-
ate lineage when inflammatory damage or injury occurs in
the nervous system [44]. To determine the functions of IL-
17 on NSC differentiation, we investigated whether IL-17
might hamper the capacity of NSCs to differentiate into
neurons, astrocytes and OPCs. While IL-17 stimulation
drove NSCs to differentiate into a smaller number of neu-
rons, astrocytes, it resulted in significantly lower numbers of
NSCs differentiating into astrocytes and OPCs, cells crucial
for remyelination [21], as well as undifferentiated NSCs.
Given that OPCs are the precursor cells of oligodendrocytes,
the only myelinating cells in the CNS, reduced OPC differ-
entiation from NSCs could be a potential mechanism of IL-
17 pathogenesis in the failure of remyelination in MS/EAE
[45]. Further, given that astrocytes play an important role in
the production of neurotrophic factors and support neural
repair [46], reduction of these cells by IL-17 would result in
incomplete neural repair after CNS damage. These results,
combined with the proinflammatory effect of IL-17 in the
peripheral immune system and in the CNS, represent a
novel mechanism underlying the failure of spontaneous
remyelination and neural repair in the pathogenesis of MS.
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Figure 5 IL-17 increases p38 MAPK level in NSCs. NSCs were cultured at 400 cells/ml in 6-well plates and treated with IL-17 for 48 h, as described
in Materials and Methods. SB203580 was added to culture medium 2 h before IL-17 was added. (a) Newly formed NSCs treated with IL-17 (25 ng/ml),
with or without addition of SB203580 (15 μM). (b) Number of NSCs treated with IL-17 (25 ng/ml), with or without addition of SB203580 (15 μM).
(c) Western blot for p38 MAPK level in NSCs. Mean percentages were determined from three independent experiments. NS, not significant.
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Conclusions
We have demonstrated that NSCs constitutively express
IL-17R, and that IL-17 significantly reduces neurosphere
formation, absolute number and cell proliferation of
NSCs, and their differentiation into neural cells. Thus,
in addition to its proinflammatory role in the immune
system, IL-17 may also play a direct role in inducing de-
myelination and blocking neuronal repair in EAE/MS.
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